This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derré A., Villéger L., Farnier M., Beucler I., Bruckert E. i wsp.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003; 34: 154–156AbifadelM.VarretM.RabèsJ.P.AllardD.OuguerramK.DevillersM.CruaudC.BenjannetS.WickhamL.ErlichD.DerréA.VillégerL.FarnierM.BeuclerI.BruckertE.i wsp.Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNat. Genet.20033415415610.1038/ng116112730697Search in Google Scholar
Adorni M.P., Cipollari E., Favari E., Zanotti I., Zimetti F., Corsini A., Ricci C., Bernini F., Ferri N.: Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017; 256: 1–6AdorniM.P.CipollariE.FavariE.ZanottiI.ZimettiF.CorsiniA.RicciC.BerniniF.FerriN.Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophagesAtherosclerosis20172561610.1016/j.atherosclerosis.2016.11.01927940374Search in Google Scholar
An D., Wei X., Li H., Gu H., Huang T., Zhao G., Liu B., Wang W., Chen L., Ma W., Zhang H., Cao S., Yuan Z.: Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci. Rep., 2015; 5: 17559AnD.WeiX.LiH.GuH.HuangT.ZhaoG.LiuB.WangW.ChenL.MaW.ZhangH.CaoS.YuanZ.Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomicsSci. Rep.201551755910.1038/srep17559468691326691006Search in Google Scholar
Arama C., Diarra I., Kouriba B., Sirois F., Fedoryak O., Thera M.A., Coulibaly D., Lyke K.E., Plowe C.V., Chrétien M., Doumbo O.K., Mbikay M.: Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS One, 2018; 13: e0192850AramaC.DiarraI.KouribaB.SiroisF.FedoryakO.TheraM.A.CoulibalyD.LykeK.E.PloweC.V.ChrétienM.DoumboO.K.MbikayM.Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian childrenPLoS One201813e019285010.1371/journal.pone.0192850581395529447211Search in Google Scholar
Bai X.Q., Peng J., Wang M.M., Xiao J., Xiang Q., Ren Z., Wen H.Y., Jiang Z.S., Tang Z.H., Liu L.S.: PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin. Chim. Acta, 2018; 483: 192–196BaiX.Q.PengJ.WangM.M.XiaoJ.XiangQ.RenZ.WenH.Y.JiangZ.S.TangZ.H.LiuL.S.PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?Clin. Chim. Acta201848319219610.1016/j.cca.2018.04.04029727700Search in Google Scholar
Banach M., Rizzo M., Nikolic D., Howard G., Howard V.J., Mikhailidis D.P.: Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol. Ther., 2017; 170: 181–191BanachM.RizzoM.NikolicD.HowardG.HowardV.J.MikhailidisD.P.Intensive LDL-cholesterol lowering therapy and neurocognitive functionPharmacol. Ther.201717018119110.1016/j.pharmthera.2016.11.00127865998Search in Google Scholar
Barale C., Bonomo K., Frascaroli C., Morotti A., Guerrasio A., Cavalot F., Russo I.: Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis., 2020; 30: 282–291BaraleC.BonomoK.FrascaroliC.MorottiA.GuerrasioA.CavalotF.RussoI.Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-upNutr. Metab. Cardiovasc. Dis.20203028229110.1016/j.numecd.2019.09.01231653513Search in Google Scholar
Berger J.M., Vaillant N., Le May C., Calderon C., Brégeon J., Prieur X., Hadchouel J., Loirand G., Cariou B.: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis, 2015; 239: 252–259BergerJ.M.VaillantN.Le MayC.CalderonC.BrégeonJ.PrieurX.HadchouelJ.LoirandG.CariouB.PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertensionAtherosclerosis201523925225910.1016/j.atherosclerosis.2015.01.01225621930Search in Google Scholar
Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Hovingh G.K.: Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA, 2015; 313: 1029–1036BesselingJ.KasteleinJ.J.DefescheJ.C.HuttenB.A.HovinghG.K.Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitusJAMA20153131029103610.1001/jama.2015.120625756439Search in Google Scholar
Blom D.J., Djedjos C.S., Monsalvo M.L., Bridges I., Wasserman S.M., Scott R., Roth E.: Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ. Res., 2015; 117: 731–741BlomD.J.DjedjosC.S.MonsalvoM.L.BridgesI.WassermanS.M.ScottR.RothE.Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES studyCirc. Res.201511773174110.1161/CIRCRESAHA.115.30707126228031Search in Google Scholar
Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M., Monsalvo M.L., Tsirtsonis K., Kim J.B., Scott R., Wasserman S.M.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014; 370: 1809–1819BlomD.J.HalaT.BologneseM.LillestolM.J.TothP.D.BurgessL.CeskaR.RothE.KorenM.J.BallantyneC.M.MonsalvoM.L.TsirtsonisK.KimJ.B.ScottR.WassermanS.M.A 52-week placebo-controlled trial of evolocumab in hyperlipidemiaN. Engl. J. Med.20143701809181910.1056/NEJMoa1316222Search in Google Scholar
Boyd J.H., Fjell C.D., Russell J.A., Sirounis D., Cirstea M.S., Walley K.R.: Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J. Innate Immun., 2016; 8: 211–220BoydJ.H.FjellC.D.RussellJ.A.SirounisD.CirsteaM.S.WalleyK.R.Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsisJ. Innate Immun.2016821122010.1159/000442976Search in Google Scholar
Bułdak Ł., Marek B., Kajdaniuk D., Urbanek A., Janyga S., Bołdys A., Basiak M., Maligłówka M., Okopień B.: Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol. Pol., 2019; 70: 511–519BułdakŁ.MarekB.KajdaniukD.UrbanekA.JanygaS.BołdysA.BasiakM.MaligłówkaM.OkopieńB.Endocrine diseases as causes of secondary hyperlipidemiaEndokrynol. Pol.20197051151910.5603/EP.a2019.0041Search in Google Scholar
Campbell J.H., Popadynec L., Nestel P.J., Campbell G.R.: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis, 1983; 47: 279–295CampbellJ.H.PopadynecL.NestelP.J.CampbellG.R.Lipid accumulation in arterial smooth muscle cells. Influence of phenotypeAtherosclerosis19834727929510.1016/0021-9150(83)90059-XSearch in Google Scholar
Cariou B., Benoit I., Le May C.: Preserved adrenal function in fully PCSK9-deficient subject. Int. J. Cardiol., 2014; 176: 499–500CariouB.BenoitI.Le MayC.Preserved adrenal function in fully PCSK9-deficient subjectInt. J. Cardiol.201417649950010.1016/j.ijcard.2014.07.05725062564Search in Google Scholar
Cederberg H., Stančáková A., Yaluri N., Modi S., Kuusisto J., Laakso M.: Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort. Diabetologia, 2015; 58: 1109–1117CederbergH.StančákováA.YaluriN.ModiS.KuusistoJ.LaaksoM.Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohortDiabetologia2015581109111710.1007/s00125-015-3528-525754552Search in Google Scholar
Chang T.J., Chiu Y.F., Sheu W.H., Shih K.C., Hwu C.M., Quertermous T., Jou Y.S., Kuo S.S., Chang Y.C., Chuang L.M.: Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population. Sci. Rep., 2015; 5: 14380ChangT.J.ChiuY.F.SheuW.H.ShihK.C.HwuC.M.QuertermousT.JouY.S.KuoS.S.ChangY.C.ChuangL.M.Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese populationSci. Rep.201551438010.1038/srep14380466038426607656Search in Google Scholar
Chen S., Cao P., Dong N., Peng J., Zhang C., Wang H., Zhou T., Yang J., Zhang Y., Martelli E.E., Naga Prasad S.V., Miller R.E., Malfait A.M., Zhou Y., Wu Q.: PCSK6-mediated corin activation is essential for normal blood pressure. Nat. Med., 2015; 21: 1048–1053ChenS.CaoP.DongN.PengJ.ZhangC.WangH.ZhouT.YangJ.ZhangY.MartelliE.E.Naga PrasadS.V.MillerR.E.MalfaitA.M.ZhouY.WuQ.PCSK6-mediated corin activation is essential for normal blood pressureNat. Med.2015211048105310.1038/nm.3920471051726259032Search in Google Scholar
Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M., Boersma E., van Geuns R.J., Serruys P.W., Kardys I., Akkerhuis K.M.: PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study. Atherosclerosis, 2016; 248: 117–122ChengJ.M.OemrawsinghR.M.Garcia-GarciaH.M.BoersmaE.van GeunsR.J.SerruysP.W.KardysI.AkkerhuisK.M.PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS studyAtherosclerosis201624811712210.1016/j.atherosclerosis.2016.03.01027015246Search in Google Scholar
Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006; 354: 1264–1272CohenJ.C.BoerwinkleE.MosleyT.H.JrHobbsH.H.Sequence variations in PCSK9, low LDL, and protection against coronary heart diseaseN. Engl. J. Med.20063541264127210.1056/NEJMoa05401316554528Search in Google Scholar
D’Ardes D., Santilli F., Guagnano M.T., Bucci M., Cipollone F.: From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press. Cardiovasc. Prev., 2020; 27: 1–8D’ArdesD.SantilliF.GuagnanoM.T.BucciM.CipolloneF.From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood PressCardiovasc. Prev.20202718Search in Google Scholar
de Carvahlo L.S., Campos A.M., Sposito A.C.: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care, 2018; 41: 364–367de CarvahloL.S.CamposA.M.SpositoA.C.Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-yearsDiabetes Care20184136436710.2337/dc17-146429180351Search in Google Scholar
Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., Seidah N.G., Prat A.: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 2012; 125: 894–901DenisM.MarcinkiewiczJ.ZaidA.GauthierD.PoirierS.LazureC.SeidahN.G.PratA.Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in miceCirculation201212589490110.1161/CIRCULATIONAHA.111.05740622261195Search in Google Scholar
Diedrich G.: How does hepatitis C virus enter cells? FEBS J., 2006; 273: 3871–3885DiedrichG.How does hepatitis C virus enter cells?FEBS J.20062733871388510.1111/j.1742-4658.2006.05379.x16934030Search in Google Scholar
Ding Z., Liu S., Wang X., Deng X., Fan Y., Shahanawaz J., Shmookler Reis R.J., Varughese K.I., Sawamura T., Mehta J.L.: Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc. Res., 2015; 107: 556–567DingZ.LiuS.WangX.DengX.FanY.ShahanawazJ.Shmookler ReisR.J.VarugheseK.I.SawamuraT.MehtaJ.L.Cross-talk between LOX-1 and PCSK9 in vascular tissuesCardiovasc. Res.201510755656710.1093/cvr/cvv17826092101Search in Google Scholar
Ding Z., Liu S., Wang X., Theus S., Deng X., Fan Y., Zhou S., Mehta J.L.: PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res., 2018; 114: 1145–1153DingZ.LiuS.WangX.TheusS.DengX.FanY.ZhouS.MehtaJ.L.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophagesCardiovasc. Res.20181141145115310.1093/cvr/cvy07929617722Search in Google Scholar
Dyrbuś K., Gąsior M., Penson P., Ray K.K., Banach M.: Inclisiran – New hope in the management of lipid disorders? J. Clin. Lipidol., 2020; 14: 16–27DyrbuśK.GąsiorM.PensonP.RayK.K.BanachM.Inclisiran – New hope in the management of lipid disorders?J. Clin. Lipidol.202014162710.1016/j.jacl.2019.11.00131879073Search in Google Scholar
Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C.: Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun., 2008; 374: 341–344FeingoldK.R.MoserA.H.ShigenagaJ.K.PatzekS.M.GrunfeldC.Inflammation stimulates the expression of PCSK9Biochem. Biophys. Res. Commun.200837434134410.1016/j.bbrc.2008.07.023257108118638454Search in Google Scholar
Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A.L.: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012; 220: 381–386FerriN.TibollaG.PirilloA.CipolloneF.MezzettiA.PaciaS.CorsiniA.CatapanoA.L.Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levelsAtherosclerosis201222038138610.1016/j.atherosclerosis.2011.11.02622176652Search in Google Scholar
Gencer B., Kronenberg F., Stroes E.S., Mach F.: Lipoprotein(a): The revenant. Eur. Heart J., 2017; 38: 1553–1560GencerB.KronenbergF.StroesE.S.MachF.Lipoprotein(a): The revenantEur. Heart J.2017381553156010.1093/eurheartj/ehx03328329241Search in Google Scholar
Gencer B., Mach F., Guo J., Im K., Ruzza A., Wang H., Kurtz C.E., Pedersen T.R., Keech A.C., Ott B.R., Sabatine M.S., Giugliano R.P., FOURIER Investigators: Cognition after lowering LDL-cholesterol with evolocumab. J. Am. Coll. Cardiol., 2020; 75: 2283–2293GencerB.MachF.GuoJ.ImK.RuzzaA.WangH.KurtzC.E.PedersenT.R.KeechA.C.OttB.R.SabatineM.S.GiuglianoR.P.FOURIER InvestigatorsCognition after lowering LDL-cholesterol with evolocumabJ. Am. Coll. Cardiol.2020752283229310.1016/j.jacc.2020.03.03932381158Search in Google Scholar
Geovanini G.R., Libby P.: Atherosclerosis and inflammation: Overview and updates. Clin. Sci., 2018; 132: 1243–1252GeovaniniG.R.LibbyP.Atherosclerosis and inflammation: Overview and updatesClin. Sci.20181321243125210.1042/CS20180306Search in Google Scholar
German C.A., Shapiro M.D.: Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs, 2020; 34: 1–9GermanC.A.ShapiroM.D.Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9BioDrugs2020341910.1007/s40259-019-00399-6Search in Google Scholar
Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., Liu T., Mohanavelu S., Hoffman E.B., McDonald S.T., Abrahamsen T.E., Wasserman S.M., Scott R., Sabatine M.S., LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, 2012; 380: 2007–2017GiuglianoR.P.DesaiN.R.KohliP.RogersW.J.SomaratneR.HuangF.LiuT.MohanaveluS.HoffmanE.B.McDonaldS.T.AbrahamsenT.E.WassermanS.M.ScottR.SabatineM.S.LAPLACE-TIMI 57 InvestigatorsEfficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 studyLancet20123802007201710.1016/S0140-6736(12)61770-XSearch in Google Scholar
Giugliano R.P., Pedersen T.R., Saver J.L., Sever P.S., Keech A.C., Bohula E.A., Murphy S.A., Wasserman S.M., Honarpour N., Wang H., Pineda A.L., Sabatine M.S., FOURIER Investigators: Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke, 2020; 51: 1546–1554GiuglianoR.P.PedersenT.R.SaverJ.L.SeverP.S.KeechA.C.BohulaE.A.MurphyS.A.WassermanS.M.HonarpourN.WangH.PinedaA.L.SabatineM.S.FOURIER InvestigatorsStroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosisStroke2020511546155410.1161/STROKEAHA.119.02775932312223Search in Google Scholar
Guillemot J., Essalmani R., Hamelin J., Seidah N.G.: Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio, 2014; 4: 741–745GuillemotJ.EssalmaniR.HamelinJ.SeidahN.G.Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?FEBS Open Bio2014474174510.1016/j.fob.2014.08.004420809325349778Search in Google Scholar
Haas M.E., Levenson A.E., Sun X., Liao W.H., Rutkowski J.M., de Ferranti S.D., Schumacher V.A., Scherer P.E., Salant D.J., Biddinger S.B.: The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation, 2016; 134: 61–72HaasM.E.LevensonA.E.SunX.LiaoW.H.RutkowskiJ.M.de FerrantiS.D.SchumacherV.A.SchererP.E.SalantD.J.BiddingerS.B.The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemiaCirculation2016134617210.1161/CIRCULATIONAHA.115.020912534585327358438Search in Google Scholar
Hoac B., Susan-Resiga D., Essalmani R., Marcinkiweicz E., Seidah N.G., McKee M.D.: Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone. Bone, 2018; 107: 45–55HoacB.Susan-ResigaD.EssalmaniR.MarcinkiweiczE.SeidahN.G.McKeeM.D.Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in boneBone2018107455510.1016/j.bone.2017.11.00229126984Search in Google Scholar
Hu J., Zhang Z., Shen W.J., Azhar S.: Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr. Metab., 2010; 7: 47HuJ.ZhangZ.ShenW.J.AzharS.Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormonesNutr. Metab.201074710.1186/1743-7075-7-47289069720515451Search in Google Scholar
Izaguirre G.: The proteolytic regulation of virus cell entry by furin and other proprotein convertases. Viruses, 2019; 11: 837IzaguirreG.The proteolytic regulation of virus cell entry by furin and other proprotein convertasesViruses20191183710.3390/v11090837678429331505793Search in Google Scholar
Karagiannis A.D., Liu M., Toth P.P., Zhao S., Agrawal D.K., Libby P., Chatzizisis Y.S.: Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr. Atheroscler. Rep., 2018; 20: 20KaragiannisA.D.LiuM.TothP.P.ZhaoS.AgrawalD.K.LibbyP.ChatzizisisY.S.Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translationCurr. Atheroscler. Rep.2018202010.1007/s11883-018-0718-x29525934Search in Google Scholar
Khademi F., Momtazi-Borojeni A.A., Reiner Ž., Banach M., Al-Rasadi K.A., Sahebkar A.: PCSK9 and infection: A potentially useful or dangerous association? J. Cell. Pysiol., 2018; 233: 2920–2927KhademiF.Momtazi-BorojeniA.A.ReinerŽ.BanachM.Al-RasadiK.A.SahebkarA.PCSK9 and infection: A potentially useful or dangerous association?J. Cell. Pysiol.20182332920292710.1002/jcp.26040Search in Google Scholar
Kockx M., Kritharides L.: Pancreatic PCSK9 and its involvement in diabetes. J. Thorac. Dis., 2019; 11: S2018–S2022KockxM.KritharidesL.Pancreatic PCSK9 and its involvement in diabetesJ. Thorac. Dis.201911S2018S202210.21037/jtd.2019.06.37Search in Google Scholar
Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., Bolognese M., Wasserman S.M.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet, 2012; 380: 1995–2006KorenM.J.ScottR.KimJ.B.KnuselB.LiuT.LeiL.BologneseM.WassermanS.M.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 studyLancet20123801995200610.1016/S0140-6736(12)61771-1Search in Google Scholar
Koskinas K.C., Windecker S., Buhayer A., Gencer B., Pedrazzini G., Mueller C., Cook S., Muller O., Matter C.M., Räber L., Heg D., Mach F.: Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin. Cardiol., 2018; 41: 1513–1520KoskinasK.C.WindeckerS.BuhayerA.GencerB.PedrazziniG.MuellerC.CookS.MullerO.MatterC.M.RäberL.HegD.MachF.Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trialClin. Cardiol.2018411513152010.1002/clc.23112649013830421481Search in Google Scholar
Kruit J.K., Groen A.K., van Berkel T.J., Kuipers F.: Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol., 2006; 12: 6429–6439KruitJ.K.GroenA.K.van BerkelT.J.KuipersF.Emerging roles of the intestine in control of cholesterol metabolismWorld J. Gastroenterol.2006126429643910.3748/wjg.v12.i40.6429410063117072974Search in Google Scholar
Kühnast S., Van Der Hoorn J.W., Pieterman E.J., van den Hoek A.M., Sasiela W.J., Gusarova V., Peyman A., Schäfer H.L., Schwahn U., Jukema J.W., Princen H.M.: Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res., 2014; 55: 2103–2112KühnastS.Van Der HoornJ.W.PietermanE.J.van den HoekA.M.SasielaW.J.GusarovaV.PeymanA.SchäferH.L.SchwahnU.JukemaJ.W.PrincenH.M.Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statinJ. Lipid Res.2014552103211210.1194/jlr.M051326417400325139399Search in Google Scholar
Labonté P., Begley S., Guévin C., Asselin M.C., Nassoury N., Mayer G., Prat A., Seidah N.G.: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology, 2009; 50: 17–24LabontéP.BegleyS.GuévinC.AsselinM.C.NassouryN.MayerG.PratA.SeidahN.G.PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expressionHepatology200950172410.1002/hep.2291119489072Search in Google Scholar
Leak T.S., Keene K.L., Langefeld C.D., Gallagher C.J., Mychaleckyj J.C., Freedman B.I., Bowden D.W., Rich S.S., Sale M.M.: Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab., 2007; 92: 145–150LeakT.S.KeeneK.L.LangefeldC.D.GallagherC.J.MychaleckyjJ.C.FreedmanB.I.BowdenD.W.RichS.S.SaleM.M.Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American populationMol. Genet. Metab.20079214515010.1016/j.ymgme.2007.05.014275282417618154Search in Google Scholar
Leiva E., Wehinger S.R., Guzmán L., Orrego R.: Role of oxidized LDL in atherosclerosis. W: Hypercholesterolemia, red.: S.A. Kumar. IntechOpen Limited, London 2015, 55–77LeivaE.WehingerS.R.GuzmánL.OrregoR.Role of oxidized LDL in atherosclerosisW:Hypercholesterolemiared.:KumarS.A.IntechOpen LimitedLondon2015557710.5772/59375Search in Google Scholar
Leritz E.C., McGlinchey R.E., Salat D.H., Milberg W.P.: Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab. Brain Dis., 2016; 31: 465–473LeritzE.C.McGlincheyR.E.SalatD.H.MilbergW.P.Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memoryMetab. Brain Dis.20163146547310.1007/s11011-016-9797-y491347426873100Search in Google Scholar
Levels J.H.M., Marquart J.A., Abraham P.R., van den Ende A.E., Molhuizen H.O.F., van Deventer S.J.H., Meijers J.C.M.: Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun., 2005; 73: 2321–2326LevelsJ.H.M.MarquartJ.A.AbrahamP.R.van den EndeA.E.MolhuizenH.O.F.van DeventerS.J.H.MeijersJ.C.M.Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer proteinInfect. Immun.2005732321232610.1128/IAI.73.4.2321-2326.2005Search in Google Scholar
Li T., Jiang S., Ni B., Cui Q., Liu Q., Zhao H.: Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int. J. Mol. Sci., 2019; 20: 4513LiT.JiangS.NiB.CuiQ.LiuQ.ZhaoH.Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018Int. J. Mol. Sci.201920451310.3390/ijms20184513Search in Google Scholar
Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41: 111–188MachF.BaigentC.CatapanoA.L.KoskinasK.C.CasulaM.BadimonL.ChapmanM.J.De BackerG.G.DelgadoV.FerenceB.A.GrahamI.M.HallidayA.LandmesserU.MihaylovaB.PedersenT.R.2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular riskEur. Heart J.20204111118810.1093/eurheartj/ehz455Search in Google Scholar
Małuch I., Walewska A., Sikorska E., Prahl A.: Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych. Post. Bioch., 2016; 62: 472–481MałuchI.WalewskaA.SikorskaE.PrahlA.Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznychPost. Bioch.201662472481Search in Google Scholar
Mannarino M.R., Sahebkar A., Bianconi V., Serban M.C., Banach M., Pirro M.: PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J. Clin. Lipidol., 2018; 12: 1123–1132MannarinoM.R.SahebkarA.BianconiV.SerbanM.C.BanachM.PirroM.PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?J. Clin. Lipidol.2018121123113210.1016/j.jacl.2018.05.012Search in Google Scholar
Mbikay M., Mayne J., Seidah N.G., Chrétien M.: Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med. Hypotheses, 2007; 69: 1010–1017MbikayM.MayneJ.SeidahN.G.ChrétienM.Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphismsMed. Hypotheses2007691010101710.1016/j.mehy.2007.03.018Search in Google Scholar
Monami M., Sesti G., Mannucci E.: PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes. Metab., 2019; 21: 903–908MonamiM.SestiG.MannucciE.PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetesDiabetes Obes. Metab.20192190390810.1111/dom.13599Search in Google Scholar
Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B.: Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med., 2000; 108: 538–546MuldoonM.F.BargerS.D.RyanC.M.FloryJ.D.LehoczkyJ.P.MatthewsK.A.ManuckS.B.Effects of lovastatin on cognitive function and psychological well-beingAm. J. Med.200010853854610.1016/S0002-9343(00)00353-3Search in Google Scholar
Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y., Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D., DiStefano P.S., Wood A., Bingham B.: Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys., 2003; 420: 55–67NaureckieneS.MaL.SreekumarK.PurandareU.LoC.F.HuangY.ChiangL.W.GrenierJ.M.OzenbergerB.A.JacobsenJ.S.KennedyJ.D.DiStefanoP.S.WoodA.BinghamB.Functional characterization of Narc 1, a novel proteinase related to proteinase K.Arch. Biochem. Biophys.2003420556710.1016/j.abb.2003.09.01114622975Search in Google Scholar
Nishikido T., Ray K.K.: Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs, 2018; 27: 287–294NishikidoT.RayK.K.Inclisiran for the treatment of dyslipidemiaExpert Opin. Investig. Drugs20182728729410.1080/13543784.2018.144243529451410Search in Google Scholar
Norata G.D., Tavori H., Pirillo A., Fazio S., Catapano A.L.: Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering. Cardiovasc. Res., 2016; 112: 429–442NorataG.D.TavoriH.PirilloA.FazioS.CatapanoA.L.Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol loweringCardiovasc. Res.201611242944210.1093/cvr/cvw194503195027496869Search in Google Scholar
Okopień B., Bułdak Ł., Bołdys A.: Current and future trends in the lipid lowering therapy. Pharmacol. Rep., 2016; 68: 737–747OkopieńB.BułdakŁ.BołdysA.Current and future trends in the lipid lowering therapyPharmacol. Rep.20166873774710.1016/j.pharep.2016.03.01627180022Search in Google Scholar
Pasta A., Cremonini A.L., Pisciotta L., Buscaglia A., Porto I., Barra F., Ferrero S., Brunelli C., Rosa G.M.: PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin. Pharmacother., 2020; 21: 353–363PastaA.CremoniniA.L.PisciottaL.BuscagliaA.PortoI.BarraF.FerreroS.BrunelliC.RosaG.M.PCSK9 inhibitors for treating hypercholesterolemiaExpert Opin. Pharmacother.20202135336310.1080/14656566.2019.170297031893957Search in Google Scholar
Pavlakou P., Liberopoulos E., Dounousi E., Elisaf M.: PCSK9 in chronic kidney disease. Int. Urol. Nephrol., 2017; 49: 1015–1024PavlakouP.LiberopoulosE.DounousiE.ElisafM.PCSK9 in chronic kidney diseaseInt. Urol. Nephrol.2017491015102410.1007/s11255-017-1505-228084558Search in Google Scholar
Perego C., Da Dalt L., Pirillo A., Galli A., Catapano A.L., Norata G.D.: Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim. Biophys. Acta Mol. Basis Dis., 2019; 1865: 2149–2156PeregoC.Da DaltL.PirilloA.GalliA.CatapanoA.L.NorataG.D.Cholesterol metabolism, pancreatic β-cell function and diabetesBiochim. Biophys. Acta Mol. Basis Dis.201918652149215610.1016/j.bbadis.2019.04.01231029825Search in Google Scholar
Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem., 2008; 283: 2363–2372PoirierS.MayerG.BenjannetS.BergeronE.MarcinkiewiczJ.NassouryN.MayerH.NimpfJ.PratA.SeidahN.G.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2J. Biol. Chem.20082832363237210.1074/jbc.M70809820018039658Search in Google Scholar
Postmus I., Trompet S., de Craen A.J., Buckley B.M., Ford I., Stott D.J., Sattar N., Slagboom P.E., Westendorp R.G., Jukema J.W.: PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J. Lipid Res., 2013; 54: 561–566PostmusI.TrompetS.de CraenA.J.BuckleyB.M.FordI.StottD.J.SattarN.SlagboomP.E.WestendorpR.G.JukemaJ.W.PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly populationJ. Lipid Res.20135456156610.1194/jlr.M033969Search in Google Scholar
Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., Braunwald E., Kastelein J.J., de Lemos J.A., Blazing M.A., Pedersen T.R. i wsp.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011; 305: 2556–2564PreissD.SeshasaiS.R.WelshP.MurphyS.A.HoJ.E.WatersD.D.DeMiccoD.A.BarterP.CannonC.P.SabatineM.S.BraunwaldE.KasteleinJ.J.de LemosJ.A.BlazingM.A.PedersenT.R.i wsp.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysisJAMA20113052556256410.1001/jama.2011.86021693744Search in Google Scholar
Ramanathan A., Gusarova V., Stahl N., Gurnett-Bander A., Kyratsous C.A.: Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PLoS One, 2016; 11: e0154498RamanathanA.GusarovaV.StahlN.Gurnett-BanderA.KyratsousC.A.Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytesPLoS One201611e015449810.1371/journal.pone.0154498484599827115873Search in Google Scholar
Ramin-Mangata S., Blanchard V., Lambert G.: Key aspects of PCSK9 inhibition beyond LDL lowering. Curr. Opin. Lipidol., 2018; 29: 453–458Ramin-MangataS.BlanchardV.LambertG.Key aspects of PCSK9 inhibition beyond LDL loweringCurr. Opin. Lipidol.20182945345810.1097/MOL.000000000000055130199407Search in Google Scholar
Ramos-Molina B., Martin M.G., Lindberg I.: PCSK1 variants and human obesity. Prog. Mol. Biol. Transl. Sci., 2016; 140: 47–74Ramos-MolinaB.MartinM.G.LindbergI.PCSK1 variants and human obesityProg. Mol. Biol. Transl. Sci.2016140477410.1016/bs.pmbts.2015.12.001608239027288825Search in Google Scholar
Ray K.K., Corral P., Morales E., Nicholls S.J.: Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options. Lancet, 2019; 394: 697–708RayK.K.CorralP.MoralesE.NichollsS.J.Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future optionsLancet201939469770810.1016/S0140-6736(19)31950-6Search in Google Scholar
Ricci C., Ruscica M., Camera M., Rossetti L., Macchi C., Colciago A., Zanotti I., Lupo M.G., Adorni M.P., Cicero A.F., Fogacci F., Corsini A., Ferri N.: PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep., 2018; 8: 2267RicciC.RuscicaM.CameraM.RossettiL.MacchiC.ColciagoA.ZanottiI.LupoM.G.AdorniM.P.CiceroA.F.FogacciF.CorsiniA.FerriN.PCSK9 induces a pro-inflammatory response in macrophagesSci. Rep.20188226710.1038/s41598-018-20425-xSearch in Google Scholar
Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr, Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Eng. J. Med., 2008; 359: 2195–2207RidkerP.M.DanielsonE.FonsecaF.A.GenestJ.GottoA.M.JrKasteleinJ.J.KoenigW.LibbyP.LorenzattiA.J.MacFadyenJ.G.NordestgaardB.G.ShepherdJ.WillersonJ.T.GlynnR.J.JUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN. Eng. J. Med.20083592195220710.1056/NEJMoa0807646Search in Google Scholar
Ridker P.M., Tardif J.C., Amarenco P., Duggan W., Glynn R.J., Jukema J.W., Kastelein J.J., Kim A.M., Koenig W., Nissen S., Revkin J., Rose L.M., Santos R.D., Schwartz P.F. i wsp.: Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Eng. J. Med., 2017; 376: 1517–1526RidkerP.M.TardifJ.C.AmarencoP.DugganW.GlynnR.J.JukemaJ.W.KasteleinJ.J.KimA.M.KoenigW.NissenS.RevkinJ.RoseL.M.SantosR.D.SchwartzP.F.i wsp.Lipid-reduction variability and antidrug-antibody formation with bococizumabN. Eng. J. Med.20173761517152610.1056/NEJMoa1614062Search in Google Scholar
Roth E.M., Goldberg A.C., Catapano A.L., Torri A., Yancopoulos G.D., Stahl N., Brunet A., Lecorps G., Colhoun H.M.: Antidrug antibodies in patients treated with alirocumab. N. Eng. J. Med., 2017; 376: 1589–1590RothE.M.GoldbergA.C.CatapanoA.L.TorriA.YancopoulosG.D.StahlN.BrunetA.LecorpsG.ColhounH.M.Antidrug antibodies in patients treated with alirocumabN. Eng. J. Med.20173761589159010.1056/NEJMc1616623Search in Google Scholar
Rouillé Y., Martin S., Steiner D.F.: Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem., 1995; 270: 26488–26496RouilléY.MartinS.SteinerD.F.Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptideJ. Biol. Chem.1995270264882649610.1074/jbc.270.44.26488Search in Google Scholar
Ruscica M., Ricci C., Macchi C., Magni P., Cristofani R., Liu J., Corsini A., Ferri N.: Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J. Biol. Chem, 2016; 291: 3508–3519RuscicaM.RicciC.MacchiC.MagniP.CristofaniR.LiuJ.CorsiniA.FerriN.Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell lineJ. Biol. Chem20162913508351910.1074/jbc.M115.664706Search in Google Scholar
Sabatine M.S.: PCSK9 inhibitors: Clinical evidence and implementation. Nat. Rev. Cardiol., 2019; 16: 155–165SabatineM.S.PCSK9 inhibitors: Clinical evidence and implementationNat. Rev. Cardiol.20191615516510.1038/s41569-018-0107-8Search in Google Scholar
Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R., FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Eng. J. Med., 2017; 376: 1713–1722SabatineM.S.GiuglianoR.P.KeechA.C.HonarpourN.WiviottS.D.MurphyS.A.KuderJ.F.WangH.LiuT.WassermanS.M.SeverP.S.PedersenT.R.FOURIER Steering Committee and InvestigatorsEvolocumab and clinical outcomes in patients with cardiovascular diseaseN. Eng. J. Med.20173761713172210.1056/NEJMoa1615664Search in Google Scholar
Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., Seshasai S.R., McMurray J.J., Freeman D.J., Jukema J.W., Macfarlane P.W., Packard C.J., Stott D.J., Westendorp R.G., Shepherd J.: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735–742SattarN.PreissD.MurrayH.M.WelshP.BuckleyB.M.de CraenA.J.SeshasaiS.R.McMurrayJ.J.FreemanD.J.JukemaJ.W.MacfarlaneP.W.PackardC.J.StottD.J.WestendorpR.G.ShepherdJ.Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trialsLancet201037573574210.1016/S0140-6736(09)61965-6Search in Google Scholar
Scamuffa N., Calvo F., Chrétien M., Seidah N.G., Khatib A.M.: Proprotein convertases: Lessons from knockouts. FASEB J., 2006; 20: 1954–1963ScamuffaN.CalvoF.ChrétienM.SeidahN.G.KhatibA.M.Proprotein convertases: Lessons from knockoutsFASEB J.2006201954196310.1096/fj.05-5491revSearch in Google Scholar
Schmidt A.F., Swerdlow D.I., Holmes M.V., Patel R.S., Fairhurst-Hunter Z., Lyall D.M., Hartwig F.P., Horta B.L., Hyppönen E., Power C., Moldovan M., van Iperen E., Hovingh G.K., Demuth I., Norman K.: PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol., 2017; 5: 97–105SchmidtA.F.SwerdlowD.I.HolmesM.V.PatelR.S.Fairhurst-HunterZ.LyallD.M.HartwigF.P.HortaB.L.HyppönenE.PowerC.MoldovanM.van IperenE.HovinghG.K.DemuthI.NormanK.PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation studyLancet Diabetes Endocrinol.201759710510.1016/S2213-8587(16)30396-5Search in Google Scholar
Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., Alborn W.E., Konrad R.J., Cao G.: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun., 2008; 370: 634–640SchmidtR.J.BeyerT.P.BenschW.R.QianY.W.LinA.KowalaM.AlbornW.E.KonradR.J.CaoG.Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivoBiochem. Biophys. Res. Commun.200837063464010.1016/j.bbrc.2008.04.00418406350Search in Google Scholar
Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., Edelberg J.M., Goodman S.G., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Mahaffey K.W., Moryusef A., Pordy R., Quintero K., Roe M.T.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Eng. J. Med., 2018; 379: 2097–2107SchwartzG.G.StegP.G.SzarekM.BhattD.L.BittnerV.A.DiazR.EdelbergJ.M.GoodmanS.G.HanotinC.HarringtonR.A.JukemaJ.W.LecorpsG.MahaffeyK.W.MoryusefA.PordyR.QuinteroK.RoeM.T.Alirocumab and cardiovascular outcomes after acute coronary syndromeN. Eng. J. Med.20183792097210710.1056/NEJMoa180117430403574Search in Google Scholar
Seidah N.G.: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets, 2009; 13: 19–28SeidahN.G.PCSK9 as a therapeutic target of dyslipidemiaExpert Opin. Ther. Targets200913192810.1517/1472822080260071519063703Search in Google Scholar
Seidah N.G.: The proprotein convertases, 20 years later. Methods Mol. Biol., 2011; 768: 23–57SeidahN.G.The proprotein convertases, 20 years laterMethods Mol. Biol.2011768235710.1007/978-1-61779-204-5_321805237Search in Google Scholar
Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M.: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A., 2003; 100: 928–933SeidahN.G.BenjannetS.WickhamL.MarcinkiewiczJ.JasminS.B.StifaniS.BasakA.PratA.ChretienM.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProc. Natl. Acad. Sci. U. S. A.200310092893310.1073/pnas.033550710029870312552133Search in Google Scholar
Seidah N.G., Hamelin J., Mamarbachi M., Dong W., Tardos H., Mbikay M., Chretien M., Day R.: cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U. S. A., 1996; 93: 3388–3393SeidahN.G.HamelinJ.MamarbachiM.DongW.TardosH.MbikayM.ChretienM.DayR.cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinasesProc. Natl. Acad. Sci. U. S. A.1996933388339310.1073/pnas.93.8.3388396188622945Search in Google Scholar
Seidah N.G., Prat A.: The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov., 2012; 11: 367–383SeidahN.G.PratA.The biology and therapeutic targeting of the proprotein convertasesNat. Rev. Drug Discov.20121136738310.1038/nrd369922679642Search in Google Scholar
Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J. Biol. Chem., 2012; 287: 19266–19274SharotriV.CollierD.M.OlsonD.R.ZhouR.SnyderP.M.Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)J. Biol. Chem.2012287192661927410.1074/jbc.M112.363382336595822493497Search in Google Scholar
Shrestha P., van de Sluis B., Dullaart R.P.F., van den Born J.: Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell. Signal., 2019; 55: 53–64ShresthaP.van de SluisB.DullaartR.P.F.van den BornJ.Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemiaCell. Signal.201955536410.1016/j.cellsig.2018.12.001Search in Google Scholar
Steffens D., Bramlage P., Scheeff C., Kasner M., Hassanein A., Friebel J., Rauch-Kröhnert U.: PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther., 2020; 20: 35–47SteffensD.BramlageP.ScheeffC.KasnerM.HassaneinA.FriebelJ.Rauch-KröhnertU.PCSK9 inhibitors and cardiovascular outcomesExpert Opin. Biol. Ther.202020354710.1080/14712598.2020.1677604Search in Google Scholar
Suchy D., Łabuzek K., Stadnicki A., Okopień B.: Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol. Rep., 2011; 63: 1335–1348SuchyD.ŁabuzekK.StadnickiA.OkopieńB.Ezetimibe – a new approach in hypercholesterolemia managementPharmacol. Rep.2011631335134810.1016/S1734-1140(11)70698-3Search in Google Scholar
Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A.: Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol., 2014; 88: 2519–2529SyedG.H.TangH.KhanM.HassaneinT.LiuJ.SiddiquiA.Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagationJ. Virol.2014882519252910.1128/JVI.02727-13Search in Google Scholar
Tadros H., Chrétien M., Mbikay M.: The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary. J. Reprod. Immunol., 2001; 49: 133–152TadrosH.ChrétienM.MbikayM.The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovaryJ. Reprod. Immunol.20014913315210.1016/S0165-0378(00)00085-1Search in Google Scholar
Tang Z.H., Peng J., Ren Z., Yang J., Li T.T., Li T.H., Wang Z., Wei D.H., Liu L.S., Zheng X.L., Jiang Z.S.: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis, 2017; 262: 113–122TangZ.H.PengJ.RenZ.YangJ.LiT.T.LiT.H.WangZ.WeiD.H.LiuL.S.ZhengX.L.JiangZ.S.New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathwayAtherosclerosis201726211312210.1016/j.atherosclerosis.2017.04.02328535426Search in Google Scholar
Taskinen M.R., Björnson E., Andersson L., Kahri J., Porthan K., Matikainen N., Söderlund S., Pietiläinen K., Hakkarainen A., Lund-bom N., Nilsson R., Ståhlman M., Adiels M., Parini P., Packard C.: Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects. J. Clin. Lipidol., 2020; 14: 77–87TaskinenM.R.BjörnsonE.AnderssonL.KahriJ.PorthanK.MatikainenN.SöderlundS.PietiläinenK.HakkarainenA.Lund-bomN.NilssonR.StåhlmanM.AdielsM.PariniP.PackardC.Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjectsJ. Clin. Lipidol.202014778710.1016/j.jacl.2019.12.00331917184Search in Google Scholar
Tavori H., Giunzioni I., Predazzi I.M., Plubell D., Shivinsky A., Miles J., Devay R.M., Liang H., Rashid S., Linton M.F., Fazio S.: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc. Res., 2016, 110: 268–278TavoriH.GiunzioniI.PredazziI.M.PlubellD.ShivinskyA.MilesJ.DevayR.M.LiangH.RashidS.LintonM.F.FazioS.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanismsCardiovasc. Res.201611026827810.1093/cvr/cvw053483663126980204Search in Google Scholar
Thomas G.: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 2002; 3: 753–766ThomasG.Furin at the cutting edge: From protein traffic to embryogenesis and diseaseNat. Rev. Mol. Cell Biol.2002375376610.1038/nrm934196475412360192Search in Google Scholar
Van Bruggen F.H., Nijhuis G.B.J., Zuidema S.U., Luijendijk H.: Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review. Expert Rev. Clin. Pharmacol., 2020; 13: 787–796Van BruggenF.H.NijhuisG.B.J.ZuidemaS.U.LuijendijkH.Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic reviewExpert Rev. Clin. Pharmacol.20201378779610.1080/17512433.2020.178783232597252Search in Google Scholar
Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F., Christie J.D., Nakada T.A., Fjell C.D., Thair S.A., Cirstea M.S., Boyd J.H.: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med., 2014; 6: 258ra143WalleyK.R.ThainK.R.RussellJ.A.ReillyM.P.MeyerN.J.FergusonJ.F.ChristieJ.D.NakadaT.A.FjellC.D.ThairS.A.CirsteaM.S.BoydJ.H.PCSK9 is a critical regulator of the innate immune response and septic shock outcomeSci. Transl. Med.20146258ra14310.1126/scitranslmed.3008782434214725320235Search in Google Scholar
Williams D.M., Finan C., Schmidt A.F., Burgess S., Hingorani A.D.: Lipid lowering and Alzheimer disease risk: A Mendelian randomization study. Ann. Neurol., 2020, 87: 30–39WilliamsD.M.FinanC.SchmidtA.F.BurgessS.HingoraniA.D.Lipid lowering and Alzheimer disease risk: A Mendelian randomization studyAnn. Neurol.202087303910.1002/ana.25642694451031714636Search in Google Scholar
Wu C.Y., Tang Z.H., Jiang L., Li X.F., Jiang Z.S., Liu L.S.: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem., 2012, 359: 347–358WuC.Y.TangZ.H.JiangL.LiX.F.JiangZ.S.LiuL.S.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathwayMol. Cell. Biochem.201235934735810.1007/s11010-011-1028-621847580Search in Google Scholar
Yano H., Horinaka S., Ishimitsu T.: Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol., 2020; 75: 289–295YanoH.HorinakaS.IshimitsuT.Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndromeJ. Cardiol.20207528929510.1016/j.jjcc.2019.08.00231495548Search in Google Scholar
Yurtseven E., Ural D., Baysal K., Tokgözoğlu L.: An update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb., 2020; 27: 909–918YurtsevenE.UralD.BaysalK.TokgözoğluL.An update on the role of PCSK9 in atherosclerosisJ. Atheroscler. Thromb.20202790991810.5551/jat.55400750872132713931Search in Google Scholar
Zheng-Lin B., Ortiz A.: Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting. Drugs, 2018; 78: 215–229Zheng-LinB.OrtizA.Lipid management in chronic kidney disease: Systematic review of PCSK9 targetingDrugs20187821522910.1007/s40265-017-0858-229299849Search in Google Scholar
Zimetti F., Caffarra P., Ronda N., Favari E., Adorni M.P., Zanotti I., Bernini F., Barocco F., Spallazzi M., Galimberti D., Ricci C., Ruscica M., Corsini A., Ferri N.: Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 315–320ZimettiF.CaffarraP.RondaN.FavariE.AdorniM.P.ZanottiI.BerniniF.BaroccoF.SpallazziM.GalimbertiD.RicciC.RuscicaM.CorsiniA.FerriN.Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s diseaseJ. Alzheimers Dis.20175531532010.3233/JAD-16041127662294Search in Google Scholar